The Activities of the Multidisciplinary Association for Psychedelic Studies as an Example of Modern US Science Diplomacy
Table of contents
The Activities of the Multidisciplinary Association for Psychedelic Studies as an Example of Modern US Science Diplomacy
Publication type
Aleksandra Rogovtseva 
Affiliation: Russian State University for the Humanities
Address: Russian Federation, Moscow

The article is devoted to the analysis of present-day international cooperation in the field of science, innovation and medicine. Using the example of the work of the Multidisciplinary Association for Psychedelic Science abroad, namely in Switzerland, Mexico and Israel, the author considers a completely new area of “diplomacy for science” — the cooperation in the study of illicit substances. Using the historical-genetic and retrospective method to immerse in the history of scientific diplomacy and psychedelic research in the territory of the selected country, the comparative method — to compare foreign and domestic political approaches, as well as using journalistic articles,  medical articles and publications in the MAPS Bulletin as sources, the author considers the reason for conducting the MDMA/PTSD, LSD/End of Life Anxiety, and Ibogaine/Addiction studies in the selected countries.

Science Diplomacy, “Diplomacy for Science”, Psychedelic Research, Interdisciplinary Association for Psychedelic Science, MDMA, LSD, Ibogaine, Swiss Medical Society for Psycholytic Therapy
Publication date
Number of characters
Number of purchasers
Readers community rating
0.0 (0 votes)
Cite Download pdf 200 RUB / 1.0 SU

To download PDF you should sign in

Full text is available to subscribers only
Subscribe right now
Only article and additional services
Whole issue and additional services
All issues and additional services for 2022


1. Abramson H. LSD in Psychotherapy and Alcoholism // American Journal of Psychotherapy. 1966. Vol. 20 (3). P. 415—438.

2. Alper K. Fatalities Temporally Associated with the Ingestion of Ibogaine // Journal of Forensic Science. Vol. 57 (2). P. 398—412.

3. Alper K. The Ibogaine Medical Subculture // The Journal of Ethnopharmacology. 2008. Vol. 115 (1). P. 9—24.

4. Becker D. Ibogaine: One Man’s Journey to Mexico for Psychedelic Addiction Treatment // WBUR. 10 September 2018 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

5. Braun T. Treatment of Opioid Use Disorder with Ibogaine: Detoxification and Drug Use Outcomes // The American Journal of Drug and Alcohol Abuse. 2017. P. 24—36.

6. Buonomo T. Middle East Science Diplomacy Focused on Psychedelics Could Generate Peace Dividends // Psychedelics Today. 23 November 2020 [Ehlektronnyj resurs]. URL: (data obrascheniya 02.01.2022).

7. Camnaji E. ALCE, el Sueño de la Conquista Latinoamericana del Espacio // El Pais. 21 Novembre 2020 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

8. Carnicella S., Ron D. GDNF — A Potential Target to Treat Addiction // Pharmacological Therapy. 2009. Vol. 122 (1). P. 9—18.

9. Comisión de Salud Fronteriza México-Estados Unidos. ¿Quiénes somos? Tijuana: Comisión de Salud Fronteriza México-Estados Unidos [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

10. DEA. Scheduling of 3,4-Methylenedioxymethamphetamine (MDMA) into Schedule I of the Controlled Substances Act // Schedules of Controlled Substances. Remand. 1988. Vol. 53 (34).

11. Doblin R. A Clinical Plan for MDMA (“Ecstasy”) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA // Journal of Psychoactive Drugs. 2002. Vol. 34 (2). P. 185—194.

12. Drug Scheduling // DEA [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

13. Fedoroff N. Science Diplomacy in the 21st Century // Cell. Vol. 136 (1). P. 9—11.

14. Feilding A. The Man who Mapped LSD // OUPBlog. 12 February 2019 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

15. Fernandez J. Returning to the Path”: the Use of Iboga[ine] in an Equatorial African Ritual Context and the Binding of Time, Space, and Social Relationships // The Alkaloids: Chemistry and Biology. 2001. Vol. 56. P. 235—247.

16. Financial Reports // MAPS [Ehlektronnyj resurs]. URL: (data obrascheniya: 11.02.2022).

17. Gasser P., Holstein D., Michel Y. Safety and Efficacy of LSD-ssisted Psychotherapy in Subjects with Anxiety Associated with Life-threatening Diseases: a Randomized Active Placebo-controlled Phase 2 Pilot Study // The Journal of Nervous and Mental Disease. 2014. Vol. 202 (7). P. 513—520.

18. Gasser P. Research Update: Psychedelic Group Therapy in Switzerland // MAPS Bulletin Spring 2017: Vol. 27. No. 1. Special Edition: Psychedelic Science. 2017 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

19. Gillmor D. I Swear by Apollo: Dr. Ewen Cameron and the CIA-brainwashing Experiments. Eden Press, 1987.

20. Ginsbert N. Early Reflections on Interviews with Palestinians and Israelis Drinking Ayahuasca Together // MAPS Bulletin Winter. Vol. 29 (3). 2019 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

21. Grinspoon L., Bakalar J. Can Drugs Be Used to Enhance the Psychotherapeutic Process? // American Journal of Psychotherapy. 1986. Vol. 40 (3). P. 393—404.

22. Grof S, Halifax J, Kübler-Ross E. The Human Encounter with Death. N. Y.: EP Dutton, 1978.

23. Ibogaine. Proceedings of the First International Conference / ed. Alper K. California. Academic press. 2001.

24. Instituto de los Mexicanos en el Exterior. ¿Qué hasemos? Mexico: Instituto de los Mexicanos en el Exterior [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

25. Israel Approves Clinical Trial to Treat PTSD with MDMA // YouTube [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.01.2022).

26. Koenig X., Hilber K. The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation // Molecules. 2015. Vol. 20 (2). P. 2208—2228.

27. Liester M. A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects // Curriculum of Drug Abuse Review. 2014. Vol. 7 (3). P. 146—156.

28. LSD & Psilocybin-Assisted Therapy for Anxiety // MAPS. 2012 [Ehlektronnyj resurs]. URL: (data obrascheniya: 11.02.2022).

29. MAPS Bulletin [Ehlektronnyj resurs]. URL: (data obrascheniya: 11.02.2022)

30. MAPS Public Benefit [Ehlektronnyj resurs]. URL: (data obrascheniya: 11.02.2022).

31. Marlow J. Could Science Diplomacy Help Israel Create a Lasting Peace? // Wired. 23 November 2012 [Ehlektronnyj resurs]. URL: (data obrascheniya 02.01.2022).

32. Montgomery K. Anticipatory Science Diplomacy: An interview with Ambassador Pitteloud // AAAS. 30 September 2021 [Ehlektronnyj resurs]. URL: (data obrascheniya: 14.02.2022).

33. Naftulin J. Oregon has Become the First State to Legalize “Magic” Mushrooms for Therapeutic Use. Here’s What That Means // Insider. 5 November 2020 [Ehlektronnyj resurs]. URL: (data obrascheniya: 24.12.2021).

34. New Frontiers of Science Diplomacy // AAAS, Royal Society. 2009 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

35. Nichols D. Differences between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens — Identification of a New Therapeutic Class: Entactogens // Journal of Psychoactive Drugs. 1986. Vol. 18 (4). P. 305—313.

36. Nichols D. Hallucinogens // Pharmacological Therapy. 2004. Vol. 101 (2). P. 131—181.

37. Osmond H. A Review of The Clinical Effects of Psychotomimetic Agents // Annals of NY Academy of Science. 1957. Vol. 66 (3). P. 418—434.

38. Parrott A. The Potential Dangers of Using MDMA for Psychotherapy // Journal of Psychoactive Drugs. 2014. Vol. 46 (1). P. 37—43.

39. Peter Gasser: Psychedelic Psychotherapy in Switzerland // YouTube [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.01.2022).

40. PREPFAR World Activities. 2011 [Ehlektronnyj resurs]. URL: (data obrascheniya: 11.02.2022).

41. Reich P. Switzerland: Government Adopts a Partial Revision of the Chemicals Control Ordinance // Baker & McKenzie’s. 19 January 2022 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

42. Roy A. United States: No. 4 in the 2020 World Index of Healthcare Innovation // FREOP. 5 September 2020 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

43. Soler M. Science Diplomacy in Latin America and the Caribbean: Current Landscape, Challenges, and Future Perspectives // Frontiers in research metrics and analytics.

44. Strozier C., Terman D., Jones J., Boyd K. The Fundamentalist Mindset: Psychological Perspectives on Religion, Violence, and History. Oxford, 2010.

45. The HEARTS Initiative is Launched in Mexico // PAHO. 18 February 2020 [Ehlektronnyj resurs]. URL: (data obrascheniya: 02.02.2022).

46. The Royal Society. New Frontiers in Science Diplomacy. Report of the Meeting Hosted by the Royal Society from 1—2 June 2009. January 2010. P. 9.

47. United States-Israel Binational Science Foundation (BSF) [Ehlektronnyj resurs]. URL: (data obrascheniya 02.01.2022).

48. Vorbrüggen M., Baer H. Humiliation: The Lasting Effect of Torture // Military Medicine. 2007. Vol. 172 (2). P. 29—33.

49. White C. 3,4-Methylenedioxymethamphetamine’s (MDMA’s) Impact on Posttraumatic Stress Disorder // Annals of Pharmacotherapy. 2014. Vol. 48 (7). P. 908—915.

50. Zendo Project [Ehlektronnyj resurs]. URL: (data obrascheniya 11.02.2022).

51. Chubaryan A., Griset P., Ruffini P., Zabotkina V. Science Diplomacy: Theory and Practice // ISTORIYA. 2021. Vol. 12. Issue 12 (110). Part 2. URL: DOI: 10.18254/S207987840018743-6

52. Kiselev V. Novoe izmerenie nauchnoj diplomatii // RSMD. 15 dekabrya 2017 [Ehlektronnyj resurs]. URL: (data obrascheniya: 22.02.2022).


No posts found

Write a review